On the Couch with Nathan Smith (Neuroscientific): Inside the StemSmart Strategy for Crohn's
About this episode
Henry Jennings interviews Nathan Smith about the StemSmart Strategy for treating Crohn's disease with stem cell therapy.
Welcome to the latest episode of On the Couch. In this episode, Henry Jennings from Marcus Today sits down with Nathan Smith, CEO of Neuroscientific Biopharmaceuticals, to unpack how a differentiated mesenchymal stem cell therapy is progressing from acquisition to patient impact in refractory Crohn's disease. With promising real-world data via special access programs, a clear regulatory path, and lean execution, the company is preparing for a focused Phase 2 push in 2026. Topics covered in t...
People in this episode
Host: Henry Jennings
Guest: Nathan Smith
Topics covered
- stem cell therapy
- Crohn's disease
- biopharmaceuticals
- patient impact
- regulatory path
Keywords
- Neuroscientific
- stem cells
- Crohn's disease
- biopharmaceuticals
- Phase 2
Mentioned in this episode
Organizations: Neuroscientific Biopharmaceuticals
Products: StemSmart Strategy
Places: Crohn's disease
More episodes of On the Couch
- On the Couch with Nick Griffin (Munro Partners): Markets, AI and Global Tech Themes
- Ask the Analyst | 17 April
- Why the Next Six Months Could Get Tough for Small Caps: On the Couch with Chris Stott
- On the Couch with Coby Hanoch (Weebit Nano): The Memory Boom Behind AI
- On the Couch With Richard Morrow (Lowell Resources): Talking Gold and Gold Stocks
- On the Couch with Gary Norden: Inside a 35-Year Trading Career
Explore listener stats, chart rankings, contacts and more on the On the Couch podcast page.